Abstract
Total fertilisation failure (TFF) is estimated to affect 4-7% IVF and 3-5% ICSI cycles1. Treatment for TFF and low-fertilisation (<30%) is challenging due to poorly understood underlying molecular mechanisms. There are no present regulations on Assisted Oocyte Activation (AOA) treatment for TFF from any ART regulatory body. The sperm protein Phospholipase C zeta (PLCζ) plays an essential role in oocyte activation, a major contributor to TFF2. However, not all TFF patients benefit from AOA. We hypothesised that retrospective analysis of the AOA treatment cohort, and development of a pre-treatment phenotypic diagnostic PLCζ assay could positively impact ART outcomes TFF patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
